At IXICO, we work with academic institutions, disease-focused charities, consortia, and biopharmaceutical companies to tackle the most complex challenges in neuroscience using our AI-driven imaging biomarker platform. IXICO's partnerships are built on shared goals: improving patient outcomes, accelerating drug development, and advancing the science of neurodegeneration.
IXICO was selected to support GAP’s Bio-Hermes-001 trial, a pioneering study aimed at evaluating a number of blood-based and digital biomarkers and comparing them to gold-standard amyloid PET scans. In addition, the trial also collected a wide range of “omics” data: proteomics and genomics for further evaluations against all the biomarkers and the imaging.
Using our IXI™ Platform, we collected and analysed PET brain scans, supported biomarker comparison, and contributed to a bio-sample database of 1,000+ volunteers. The trial uses Amyvid™ to measure β-amyloid plaque density in subjects ranging from cognitively normal, through MCI and mild AD.
IXICO continues as GAP’s imaging partner on the Bio-Hermes-002 follow-on study. This collaboration is part of this unique, observational platform study that compares blood-based and digital biomarkers across 1,000 participants who range from cognitively normal, through MCI and mild-moderate AD. The trial aims, in addition, to recruit a minimum of 25% of participants from under-represented populations and is being run at sites in North America, Canada and the UK.
This collaboration reflects a shared commitment to inclusive research, with Bio-Hermes enrolling a diverse participant population to ensure that potential AD diagnostics are fully evaluated across ethnicities and demographics.
The HD-IH Consortium is a collaborative initiative dedicated to creating a standardised advanced neuroimaging dataset using regulatory-grade analysis pipelines and algorithms to better characterise Huntington’s disease (HD) progression.
Founded by leading HD organisations, the HD-IH curated and analysed over 6,000 MRI scans from more than 2,000 participants across landmark studies such as IMAGE-HD, PREDICT-HD, TRACK-HD, and TrackOn-HD. IXI™ platform’s IXIQ.Ai algorithms were used in HD-IH for the analysis of imaging endpoints that are important for decision-making in HD clinical trials.
Consortium members (in alphabetical order):
Our goal:
To create a unified high-quality morphometric dataset analysed with industry-grade pipelines to support enhanced clinical trial design and participant selection, and to aid in the development of HD biomarkers with the rigour and quality control of regulatory requirements.
Key contributions include:
Why regulatory-grade datasets matter
Structural MRI biomarkers—like volumetric changes in the caudate and putamen—may be important tools to stratify people with HD, for their participation in research, and to monitor disease progression. HD-IH’s harmonised analysis supports:
Get involved
Whether you're a researcher, clinician, or sponsor, HD-IH welcomes new members to join the consortium and collaborate to advance imaging science in HD.
IXICO supports Friedreich’s Ataxia (FA) research through partnership with FARA. We are an industry partner in the TRACK-FA study—the largest multi-modal imaging study in FA to date. Separately, we also partner with biotech sponsors and are providing imaging services for an industry-sponsored Phase 1b trial. Our AI tools help identify imaging biomarkers of disease progression to support early intervention strategies in the future.
By advancing imaging science in rare diseases like FA, IXICO is helping to close the evidence gap and enable more inclusive, biomarker-driven clinical trials for underserved patient populations.
AMYPAD were a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging. Our aims were:
The AMYPAD consortium was a combination of 9 academic partners, 3 industrial partners, 2 SMEs and 1 patient organisation. AMYPAD has addressed its goals in close collaboration with IMI project EPAD in a public-private partnership. In addition, regular interactions and synergies with external experts and complementary initiatives have been established, fostering the attainment of the AMYPAD project objective
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a longitudinal, multi-centre, observational study. The overall goal of ADNI is to validate biomarkers for Alzheimer’s disease (AD) clinical trials.
The ADNI study actively supports the investigation and development of treatments that slow or stop the progression of Alzheimer’s disease (AD). Researchers at over 60 clinical sites in the USA and Canada collect data to study the progression of AD in the human brain across normal aging, mild cognitive impairment (MCI), and Alzheimer’s disease and dementia
The AI Centre is led by King’s College London and Guy's and Thomas’ NHS Foundation Trust, alongside multiple NHS Trusts, Universities and UK and multi-national industry partners.
Established in February 2019, we were originally funded by Innovate UK Office of Life Sciences (OLS), and now are funded by the Department of Health and Social Care (DHSC), One London SDE, Genomics England and KHP Health partners as well as grants and innovation projects.
We focus on deep multi-modal data engineering and language AI, to facilitate deep phenotyping for clinical research, Software-as-Medical Device development, biomarker development (precision medicine), and Foundation Model training;
As part of our commitment to supporting the development and implementation of robust, secure, and trustworthy clinical AI we are also carrying out pioneering work in establishing ethics and data governance models
Reach out to explore partnership opportunities in clinical trials, research, or technology innovation
Contact us
